Scott Palmer, MD
Urology · Fort Wayne, INNPI 1598776668
Payments from drug & device makers
Across 94 payments — averaging $30.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$2K
- Sumitomo Pharma America, Inc.$305
- Boston Scientific$141
- AbbVie$113
- Pfizer$64
- 180 Medical, Inc.$56
- plus $471 from 17 others
What the payments were for
- Travel & lodging$1,50453%
- Food & beverage$1,31947%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 11 | $1,673 |
| Sumitomo Pharma America, Inc. | 37 | $305 |
| Boston Scientific | 4 | $141 |
| AbbVie | 7 | $113 |
| Pfizer | 4 | $64 |
| 180 Medical, Inc. | 2 | $56 |
| Laborie Medical Technologies Corp. | 4 | $55 |
| Merck | 2 | $49 |
| Teleflex LLC | 3 | $49 |
| Axonics, Inc. | 2 | $36 |
| EDAP Technomed Inc | 3 | $33 |
| Johnson & Johnson | 2 | $32 |
| Astellas Pharma US Inc | 2 | $30 |
| Blue Earth Diagnostics | 1 | $28 |
| Endo USA, Inc. | 1 | $24 |
| Travere Therapeutics, Inc. | 2 | $23 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| ABC Home Medical Supply, Inc. | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $18 |
| Urovant Sciences Inc | 1 | $16 |
| Ambu Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Calyxo, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$1,488
How this compares
$2,823 in reported general payments places this provider in the 45th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 133 | $119,238 |
| MyrbetriqMirabegron | 128 | $117,062 |
| ElmironPentosan Polysulfate Sodium | 31 | $40,301 |
| Dutasteride | 788 | $23,150 |
| Tamsulosin Hcl | 1,836 | $21,737 |
| Potassium Citrate ErPotassium Citrate | 87 | $9,522 |
| Oxybutynin Chloride ErOxybutynin Chloride | 199 | $5,916 |
| PremarinEstrogens, Conjugated | 11 | $5,861 |
| Estradiol | 87 | $5,094 |
| Testosterone | 19 | $5,086 |
| Finasteride | 619 | $4,292 |
| Solifenacin Succinate | 68 | $4,068 |
| Silodosin | 37 | $3,773 |
| Methenamine Hippurate | 37 | $3,727 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 12 | $2,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $305 | $119,238133 claims |
| Astellas Pharma US IncMyrbetriq | $30 | $117,062128 claims |
| PfizerPremarin | $64 | $5,86111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 272 urology providers in Indiana.
Other urology in Fort Wayne
- Colin LinkeFort Wayne$65K
- Mark DabagiaFort Wayne$27K
- Jorge ArzolaFort Wayne$19K
- George MartinFort Wayne$16K
- Ryan MaloneJeffersonville$7.1M
- James BailenJeffersonville$5.9M
- Eugene ConeGreenwood$2.1M
- Chad ReichardCarmel$1.3M
- Alexander TatemCarmel$441K
- Marcelino RiveraIndianapolis$382K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.